Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LOXL1 Double Nickase Plasmid (h): sc-401965-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LOXL1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LOXL1 Double Nickase Plasmid (h) and LOXL1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LOXL1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LOXL1 Antibody (H-11): sc-166632
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LOXL1 Double Nickase Plasmid (h) | sc-401965-NIC | 20 µg | $410.00 | |||
LOXL1 Double Nickase Plasmid (h2) | sc-401965-NIC-2 | 20 µg | $410.00 |
LOXL1 encodes lysyl oxidase–like 1, a copper-dependent amine oxidase that catalyzes oxidative deamination of lysine residues in elastin and collagen, promoting covalent crosslinking and maturation of the extracellular matrix. Through regulation of elastogenesis and collagen fibrillogenesis, LOXL1 contributes to tissue mechanical stability, cell–matrix signaling, and remodeling processes linked to wound repair and fibrosis-associated pathways. Altered LOXL1 activity or expression has been associated with extracellular matrix dysregulation observed in disorders such as exfoliation syndrome/exfoliation glaucoma and connective tissue remodeling phenotypes. In cancer biology and stromal research, LOXL1 is studied for its role in matrix organization and its potential impact on invasion-permissive microenvironments.
LOXL1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LOXL1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LOXL1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LOXL1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LOXL1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.